What Affects Relapse After Desmopressin Treatment in Monosymptomatic Nocturnal Enuresis?

Background: Desmopressin is an important treatment option for monosymptomatic nocturnal enuresis (MEN), yet relapse after discontinuation remains a major problem. This study aimed to compare the outcomes of different desmopressin formulations (orally fast-dissolving lyophilized vs. sublingual tablet) used in MEN treatment and to examine the recurrence rates of gradual versus sudden discontinuation.

Methods: Patients who received desmopressin treatment with a diagnosis of MEN from a single center (Dec 2022–Aug 2023) were retrospectively analyzed. Desmopressin treatment (136 in fast-dissolving lyophilized form, 98 in sublingual tablet) was started in 234 patients (75 girls, 159 boys) (mean age 9.26 years) (preschooler 72, preadolescent 135, adolescence 27), was given for an average of 3.1 months, and was terminated (suddenly 204, gradually 30 patients). Afterwards, the patients were evaluated with follow-up visits in the first and third months, and statistical analyses were performed.

Results: There were no significant differences in relapse rates among patients with different drug formulations or discontinuation methods. However, preschool children (5-7 years of age) had significantly lower relapse rates than older age groups (P = .004 and P = .018). No dose-related differences in relapse were found.

Conclusion: Age was the main determinant of relapse, with preschool children exhibiting better sustained responses. Drug formulation and discontinuation method did not significantly affect relapse. The fast-dissolving form may improve treatment adherence due to ease of administration.

Cite this article as: Yayla D. What affects relapse after desmopressin treatment in monosymptomatic nocturnal enuresis?. Turk J Nephrol. Published online February 23, 2026. doi: 10.5152/turkjnephrol.2026.251127.